These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29368043)

  • 1. Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study.
    Hollis K; Proctor C; McBride D; Balp MM; McLeod L; Hunter S; Tian H; Khalil S; Maurer M
    Am J Clin Dermatol; 2018 Apr; 19(2):267-274. PubMed ID: 29368043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison and interpretability of the available urticaria activity scores.
    Hawro T; Ohanyan T; Schoepke N; Metz M; Peveling-Oberhag A; Staubach P; Maurer M; Weller K
    Allergy; 2018 Jan; 73(1):251-255. PubMed ID: 28815631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Urticaria Activity Score-Validity, Reliability, and Responsiveness.
    Hawro T; Ohanyan T; Schoepke N; Metz M; Peveling-Oberhag A; Staubach P; Maurer M; Weller K
    J Allergy Clin Immunol Pract; 2018; 6(4):1185-1190.e1. PubMed ID: 29128337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria.
    Stull D; McBride D; Tian H; Gimenez Arnau A; Maurer M; Marsland A; Balp MM; Khalil S; Grattan C
    Br J Dermatol; 2017 Oct; 177(4):1093-1101. PubMed ID: 28295198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study).
    Jauregui I; Gimenez-Arnau A; Bartra J; Labrador-Horrillo M; de Frutos JO; Silvestre JF; Sastre J; Velasco M; Ferrer M; Ballesteros C; Valero A
    Health Qual Life Outcomes; 2019 Jan; 17(1):23. PubMed ID: 30704532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool.
    Maurer M; Mathias SD; Crosby RD; Rajput Y; Zazzali JL
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):641-647. PubMed ID: 29567359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Urticaria Biomarkers IL-6, ESR and CRP in Correlation with Disease Severity and Patient Quality of Life-A Pilot Study.
    Kuna M; Štefanović M; Ladika Davidović B; Mandušić N; Birkić Belanović I; Lugović-Mihić L
    Biomedicines; 2023 Aug; 11(8):. PubMed ID: 37626727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
    Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
    Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Amyloid A as a Potential Biomarker for Disease Activity in Chronic Spontaneous Urticaria.
    Carvallo A; Veleiro B; Sabaté-Brescó M; Baeza ML; Guilarte M; Herrera-Lasso V; Rodríguez-Garijo N; Diaz Donado C; Labrador-Horrillo M; Ferrer M
    J Allergy Clin Immunol Pract; 2024 Jan; 12(1):195-200. PubMed ID: 37716523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jia HX; He YL
    Am J Ther; 2020; 27(5):e455-e467. PubMed ID: 32427616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probiotic as an adjuvant therapy in chronic urticaria: a blinded randomized controlled clinical trial.
    Atefi N; Fallahpour M; Sharifi S; Ghassemi M; Roohaninasab M; Goodarzi A
    Eur Ann Allergy Clin Immunol; 2022 May; 54(3):123-130. PubMed ID: 33939347
    [No Abstract]   [Full Text] [Related]  

  • 13. The validity and reliability of the Thai-version of 5-D itch scale.
    Tuchinda P; Kulthanan K; Chularojanamontri L; Rujitharanawong C; Subchookul C; Trakanwittayarak S
    Asian Pac J Allergy Immunol; 2022 Sep; 40(3):254-262. PubMed ID: 32247306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
    Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
    Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.
    Mathias SD; Crosby RD; Zazzali JL; Maurer M; Saini SS
    Ann Allergy Asthma Immunol; 2012 Jan; 108(1):20-24. PubMed ID: 22192960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study).
    Lacour JP; Khemis A; Giordano-Labadie F; Martin L; Staumont-Salle D; Hacard F; Tian H; McBride D; Hollis K; Hunter S; Martin L; Lamirand A; Le Guen S; Balp MM; Berard F
    Eur J Dermatol; 2018 Dec; 28(6):795-802. PubMed ID: 30698148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Arabic Urticaria Activity Score and Chronic Urticaria Quality of Life Questionnaire: validation and correlations.
    Tawil S; Irani C; Kfoury R; Salameh P; Baiardini I; Weller K; Maurer M; Ezzedine K
    Int J Dermatol; 2020 Aug; 59(8):893-901. PubMed ID: 32638368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Concentration of IL-5 Receptor (IL-5R) and Associations with Disease Severity in Patients with Chronic Spontaneous Urticaria (CSU) and Atopic Dermatitis (AD).
    Gomułka K; Tota M; Laska J; Gojny K; Sędek Ł
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.
    Kolkhir P; Laires PA; Salameh P; Asero R; Bizjak M; Košnik M; Dissemond J; van Doorn M; Hawro T; Kasperska-Zajac A; Zajac M; Kocatürk E; Peter J; Parisi CAS; Ritchie CA; Kulthanan K; Tuchinda P; Fomina D; Kovalkova E; Khoshkhui M; Kouzegaran S; Papapostolou N; Du-Thanh A; Kamegashira A; Meshkova R; Vitchuk A; Bauer A; Grattan C; Staubach P; Bouillet L; Giménez-Arnau AM; Maurer M; Weller K
    J Allergy Clin Immunol Pract; 2023 Feb; 11(2):610-620.e5. PubMed ID: 36481420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The minimal important difference for measures of urticaria disease activity: Updated findings.
    Mathias SD; Crosby RD; Rosén KE; Zazzali JL
    Allergy Asthma Proc; 2015; 36(5):394-8. PubMed ID: 26314821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.